Depression: EU approves expanded use of esketamine for rapid reduction of symptoms

Esketamine nasal spray—sold under the name Spravato—has been approved by the European Commission as a short term treatment for adults with a moderate to severe episode of major depressive disorder.1 The spray, which must be given alongside an oral antidepressant, has been approved for use in situations deemed a psychiatric emergency, to reduce depressive symptoms rapidly. The treatment was initially approved by the …